HealthcareServices

Typhoid Vi Polysaccharide Vaccine Market Outlook 2026–2030: Key Business Drivers and Trends

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the typhoid vi polysaccharide vaccine market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Typhoid Vi Polysaccharide Vaccine Market by the end of 2030?

The typhoid Vi polysaccharide vaccine market size has seen rapid growth recently. It is set to expand from $6.71 billion in 2025 to $7.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.1%. This historical growth can be attributed to the broadening of national immunization schedules, a greater awareness of typhoid prevention, the availability of polysaccharide vaccine formulations, the increase in public vaccination campaigns, and backing from global health organizations.

The typhoid vi polysaccharide vaccine market is poised for significant expansion in the coming years, with projections indicating it will reach $15.51 billion by 2030, driven by a compound annual growth rate (CAGR) of 18.3%. This anticipated growth stems from an intensified focus on mass immunization in endemic regions, greater investments in vaccine manufacturing capacity, the broadening scope of adult vaccination programs, a heightened emphasis on travel-related immunization, and the wider implementation of enhanced vaccine storage technologies. Key trends during this period include an uptick in government-led immunization campaigns, a surging demand for pediatric vaccination coverage, a heightened commitment to preventive healthcare strategies, the proliferation of collaborative public-private models for vaccine distribution, and increased attention to optimizing the cold chain.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

What Drivers Are Shaping Future Opportunities In The Typhoid Vi Polysaccharide Vaccine Market?

The increasing incidence of typhoid is projected to boost the expansion of the typhoid Vi polysaccharide vaccine market in the future. This potentially deadly infection, caused by Salmonella Typhi bacteria, commonly spreads via consumption of tainted food or beverages. Factors contributing to this surge in typhoid cases include inadequate sanitation, polluted water supplies, swift urban development, and heightened contact with impure food and water. The typhoid Vi polysaccharide vaccine market facilitates this trend by supplying vaccinations for individuals aged 2 and above, granting immunity against Salmonella enterica serovar Typhi and mitigating the impact of typhoid fever in affected areas. As an illustration, figures from the UK Health Security Agency in August 2024 indicated an uptick in lab-verified symptomatic enteric fever cases across England, Wales, and Northern Ireland, with S. Typhi cases totaling 313, S. Paratyphi A cases at 135, and S. Paratyphi B cases at 18. Consequently, the escalating occurrence of typhoid is a key impetus for the expansion of the typhoid Vi polysaccharide vaccine market.

Which Segment Groups Are Influencing The Typhoid Vi Polysaccharide Vaccine Market?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

How Are New Market Trends Shaping The Landscape Of The Typhoid Vi Polysaccharide Vaccine Market?

Leading firms within the typhoid Vi polysaccharide vaccine market are aiming to bolster their standing by making strategic investments, including funding collaborations for advanced vaccine delivery systems, in order to drive innovation and extend worldwide immunization coverage. These funding collaborations for future vaccine delivery platforms involve joint investment efforts focused on creating better typhoid vaccination methods, specifically those that are needle-free, stable at varying temperatures, and simple to use, thereby improving access, reach, and adherence in areas with limited resources. As an example, in August 2023, SK Bioscience, a biotech company based in South Korea, alongside Vaxxas, an Australian biotechnology firm known for needle-free vaccine application, obtained AUD 0.0054 billion (USD 0.00367 billion) in financing from Wellcome, a charitable foundation from the UK. This funding is for the development of a typhoid conjugate vaccine to be administered using a needle-free high-density microarray patch (HD-MAP). This innovative solution employs a micro-projection patch, removing the requirement for conventional needles; it offers thermostability, facilitating distribution in regions with poor infrastructure; and it provides the possibility of straightforward, painless administration, all with the goal of increasing global adoption of typhoid vaccination.

Who Are The Major Companies Operating In The Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Typhoid Vi Polysaccharide Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

Browse Through More Reports Similar to the Global Typhoid Vi Polysaccharide Vaccine Market 2026, By The Business Research Company

Chickenpox Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795